- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 01.05. | RADIOPHARM THERANOSTICS LIMITED: Financial Services and Company Secretary Changes | - | ASX | ||
| 23.04. | Radiopharm Theranostics Reports Business Update | 208 | GlobeNewswire (Europe) | Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI... ► Artikel lesen | |
| 23.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 20.04. | Radiopharm presents early data on HER2-targeted cancer therapy | 1 | Investing.com | ||
| 19.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Initial Findings from Phase 1 177Lu-RAD202 Trial | - | ASX | ||
| 16.04. | Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases | 187 | GlobeNewswire (Europe) | Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial... ► Artikel lesen | |
| 16.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Completes Enrollment in Phase 2b Trial of RAD 101 | - | ASX | ||
| 08.04. | Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial | 247 | GlobeNewswire (Europe) | SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 08.04. | RADIOPHARM THERANOSTICS LIMITED: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 | 1 | ASX | ||
| 07.04. | Radiopharm schließt Liefervertrag mit Siemens Healthineers für Hirntumor-Diagnostikum | 79 | Investing.com Deutsch | ||
| 07.04. | Radiopharm signs supply deal with Siemens for brain cancer drug | 14 | Investing.com | ||
| 07.04. | Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101 | 33 | RTTNews | ||
| 07.04. | Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. | 717 | GlobeNewswire (Europe) | Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures... ► Artikel lesen | |
| 07.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.04. | RADIOPHARM THERANOSTICS LIMITED: RAD and Siemens Sign Clinical Supply Agreement for RAD101 | - | ASX | ||
| 31.03. | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (IT) | 8 | ASX | ||
| 27.03. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Radiopharm doses first patient in RAD 402 prostate cancer trial | 1 | Investing.com |
1 2 3 4 5 Weiter >>
82 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| MODERNA | 43,070 | -5,06 % | JEFFERIES stuft Moderna auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Moderna auf "Hold" mit einem Kursziel von 45 US-Dollar belassen. Andrew Tsai bezog am Dienstag Stellung zur jüngsten Kursstärke... ► Artikel lesen | |
| VALNEVA | 2,530 | -1,40 % | Valneva-Aktie vor Zahlen: Was ist am 13. Mai zu erwarten? | Die Aktie von Valneva bleibt auch nach der jüngsten Kapitalspritze unter Druck. Nachdem bereits in unserem vorherigen Artikel auf die begrenzten Erholungschancen hingewiesen wurde, bestätigt die aktuelle... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 19,000 | -3,55 % | Palatin Technologies: Lizenzvereinbarung treibt Umsatz im dritten Quartal an und beflügelt die Aktie | ||
| VIVOSIM LABS | 1,290 | -1,53 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,110 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,360 | +3,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,650 | -1,08 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| XOMA ROYALTY | 35,200 | -1,12 % | XOMA Royalty Corp - 10-Q, Quarterly Report | ||
| CELLECTAR BIOSCIENCES | 2,910 | -0,34 % | Cellectar Biosciences Q1 2026 Earnings Preview | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech raises $4.2M through warrant exercise deal | ||
| NOVOCURE | 15,735 | +0,90 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,137 | +1,84 % | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen | |
| TRAWS PHARMA | 1,720 | +2,38 % | Traws Pharma, Inc.: Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections | NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,010 | -14,10 % | Moleculin Biotech, Inc.: Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits | Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier... ► Artikel lesen |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,51 % bei einem Aktienkurs von 4,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.